After Hours
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility.
Stocks Info
Beam Therapeutics Inc is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. The current market capitalization of Beam Therapeutics Inc is $2.51B. A total of 3.62 million shares were traded on the day, compared to an average of 2.58M shares.
In the most recent transaction, FMR LLC sold 459 shares of BEAM for 26.68 per share on Oct 27 ’25. After the transaction, the insider now owns 14 company shares. In a previous transaction on Oct 01 ’25, Cavanagh Bethany J sold 467 shares at 24.53 per share. BEAM shares that SVP, Finance and Treasurer owns now total 44,045.
Among the insiders who sold shares, Bellon Christine disposed of 373 shares on Oct 01 ’25 at a per-share price of $24.53. This resulted in the Chief Legal Officer holding 116,921 shares of BEAM after the transaction. In another insider transaction, Evans John M. sold 25,000 shares at $24.63 per share on Oct 02 ’25. Company shares held by the CEO now total 986,667.
Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. In terms of 52-week highs and lows, BEAM has a high of $35.25 and a low of $13.52.
As of this writing, BEAM has an earnings estimate of -$1.12 per share for the current quarter. EPS was calculated based on a consensus of 13.0 estimates, with a high estimate of -$0.9 per share and a lower estimate of -$1.28. The company reported an EPS of -$1.09 in the last quarter
Balance Sheet Annually/Quarterly
As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. BEAM’s latest balance sheet shows that the firm has $965.65M in Cash & Short Term Investments as of fiscal 2021. There were $142.35M in debt and $213.44M in liabilities at the time. Its Book Value Per Share was $9.53, while its Total Shareholder’s Equity was $826.74M.
Analysts Opinion
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BEAM is Buy with a score of 4.63.
